Tenaya Therapeutics (TNYA) Common Equity (2020 - 2026)

Tenaya Therapeutics has reported Common Equity for 7 years, with the latest figure at $106.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 11.06% year-over-year to $106.2 million; the trailing twelve-month figure through Mar 2026 stood at $106.2 million (down 11.06% YoY), and the FY2025 full-year result was $123.3 million, up 32.75% from the prior year.
• Common Equity for Q1 2026 stood at $106.2 million, down from $123.3 million in the prior quarter.
• The five-year high for Common Equity was $249.1 million in Q1 2022, with the low at $82.9 million in Q3 2025.
• Average Common Equity over 5 years is $156.0 million, with a median of $139.4 million recorded in 2023.
• Year-over-year, Common Equity soared 365.16% in 2022 and slumped 42.71% in 2023.
• Tracing TNYA's Common Equity over 5 years: stood at $243.4 million in 2022, then tumbled by 42.71% to $139.4 million in 2023, then tumbled by 33.4% to $92.9 million in 2024, then soared by 32.75% to $123.3 million in 2025, then declined by 13.85% to $106.2 million in 2026.
• The last three Common Equity figures came in at $106.2 million (Q1 2026), $123.3 million (Q4 2025), and $82.9 million (Q3 2025), per Business Quant data.

Peer Comparison